Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
SCDARIC-33 by Regeneron Pharmaceuticals for Refractory Acute Myeloid Leukemia: Likelihood of Approval
SCDARIC-33 is under clinical development by Regeneron Pharmaceuticals and currently in Phase I for Refractory Acute Myeloid Leukemia. According to...
Data Insights
SCDARIC-33 by Regeneron Pharmaceuticals for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
SCDARIC-33 is under clinical development by Regeneron Pharmaceuticals and currently in Phase I for Relapsed Acute Myeloid Leukemia. According to...